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Abstract 14	  
Studies investigating Xpert MTB/RIF diagnostic performance on cerebro-spinal fluid samples 15	  
are lacking in resource rich settings. Xpert MTB/RIF results for 740 CSF samples from 698 16	  
patients across England were retrospectively compared with the results of culture of the 17	  
same and contemporary samples. The overall sensitivity was calculated at 55%. 18	  
 19	  
 20	  
 21	  
Central nervous system infection, particularly meningitis, caused by Mycobacterium 22	  
tuberculosis occurs in around 1% of all cases of tuberculosis and accounts for at least 5% of 23	  
extra-pulmonary tuberculosis diagnoses1. It is more common in children and patients with 24	  
HIV and delayed diagnosis is associated with poor outcomes2. Laboratory diagnosis of 25	  
tuberculous meningitis (TBM) is challenging due to paucibacillary disease. Examining large 26	  
volumes of cerebrospinal fluid (CSF) improves the sensitivity of smear and culture3, but 27	  
	   2	  
volumes submitted for mycobacterial culture are often small. Thus in the majority of patients, 28	  
TBM is diagnosed on the basis of clinical symptoms, cell count and protein concentration in 29	  
the CSF rather than microbiological confirmation. The clinical value of culture remains limited 30	  
to diagnostic confirmation and drug susceptibility testing; cultures may take several weeks to 31	  
yield a positive result and negative results do not exclude TBM. 32	  
The Xpert MTB/RIF is an automated real-time molecular assay for rapid diagnosis of 33	  
tuberculosis (TB) and detection of rifampin resistance. It was first endorsed by the World 34	  
Health Organization (WHO) in December 2010. A recent systematic review reported the 35	  
successful use of the Xpert MTB/RIF test on CSF samples, with a median sensitivity of 36	  
85%4. The review included 10 studies representing a total of 126 positive CSF samples; one 37	  
study from Vietnam contributed 103 positive samples5. The second largest study was 38	  
conducted in Italy including a total of 150 CSF samples of which 11 were TB culture positive 39	  
6. Despite its wide availability, studies investigating the diagnostic performance of Xpert 40	  
MTB/RIF for TBM in resource rich settings are lacking. This study used routine retrospective 41	  
data to determine the sensitivity and specificity of Xpert MTB/RIF compared to liquid 42	  
Mycobacteria Growth Indicator Tube (MGIT)-based culture of CSF samples.  43	  
All CSF samples referred for Xpert MTB/RIF testing to the National Mycobacterium 44	  
Reference Laboratory (NMRL), London between January 2011 and January 2015 were 45	  
included in this analysis. The following data was extracted from the laboratory database: 46	  
age, gender; Xpert MTB/RIF, culture and smear results. CSF samples for which Xpert/RIF 47	  
testing was attempted were included in the analysis: a total of 741 samples with 740 valid 48	  
Xpert MTB/RIF results and one test failure. Any CSF or central nervous system culture 49	  
results from the same patient within three months of the index sample were reviewed.  Only 50	  
aliquots of >500µl underwent Xpert MTB/RIF testing to ensure sufficient sample volumes for 51	  
culture. Microscopy was performed at the NMRL if microscopy results were not available 52	  
from the referring laboratory, then up to 1.5ml of the primary sample was centrifuged, and 53	  
any supernatant in excess of 600µl was removed and the centrifuged sample was mixed 54	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with Cepheid sample reagent. Following incubation for 15 minutes 2ml of the preparation 55	  
were transferred into an Xpert MTB/RIF cartridge as per the manufacturer’s instructions. The 56	  
remaining CSF was inoculated into a Bactec MGIT tube (Becton Dickinson, Oxford, UK) and 57	  
Kirchner medium and incubated for 8 weeks.  58	  
Sensitivity and specificity and corresponding 95% confidence intervals (95%CI) of 59	  
Xpert MTB/RIF were calculated using two gold standards: firstly comparison with the culture 60	  
result on the same sample (table 1); secondly comparison with a composite of the culture 61	  
result on the same sample and any sample within 7 days of the index sample (table 2). 62	  
Samples with a positive Xpert MTB/RIF result and a negative culture result were excluded if 63	  
the patient was receiving anti-tuberculous treatment at the time of sampling.  A total of 740 64	  
samples were analysed from 698 patients: the median age was 46 (range 0 – 93 yrs), 59% 65	  
were male. TBM was confirmed by culture of the primary specimen in 37 of 740 cases 66	  
(4.5%). Including a further 8 samples with contemporary positive CSF or central nervous 67	  
system cultures for M. tuberculosis increased the prevalence to 5.5% in this series. Seven of 68	  
740 specimens were smear positive, four of which were positive on both culture and Xpert 69	  
MTB/RIF. Of the remaining 3 specimens all were culture and Xpert MTB/RIF negative for M. 70	  
tuberculosis, a non-tubercular mycobacterium was cultured in one case. Based on the Xpert 71	  
MTB/RIF and culture results on the same sample, the Xpert MTB/RIF sensitivity, specificity, 72	  
positive predictive value and negative predictive values were calculated as: 54% (95% CI 38 73	  
- 70%); 98% (95% CI 97-99%); 60% (95%CI 44-77%) and 97% (95%CI 96-98%). Table 2 74	  
takes into account contemporary positive culture results for Xpert MTB/RIF positive samples 75	  
(n=5), and Xpert MTB/RIF negative samples (n=3), improving sensitivity to 56% (95% CI 40-76	  
70.4%) and specificity to 99% (95%CI 98-99%)  77	  
 Overall Xpert MTB/RIF’s sensitivity for detecting MTB in CSF was 55%. This is 78	  
similar to the 59% determined by Nhu et al ’s study of 379 patients with probable TBM 5 and 79	  
Patel at al’s figure of 62% in their South African study of over 200 predominantly HIV positive 80	  
patients6. However it is significantly lower than the 85% sensitivity reported in an Italian 81	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study including only 11 MTB cases7. These studies utilised clinical diagnosis as well as 82	  
culture as the reference standard reflecting the difficulties in diagnosing MTB 83	  
microbiologically. Unfortunately clinical and laboratory information such as cell count are 84	  
rarely provided to the NMRL by the referring hospital, making it impossible to use a 85	  
composite reference standard such as that proposed by Marais et al8. Differences in 86	  
reference standards, make head-to-head comparison with the other studies difficult. 87	  
The Vietnamese study was conducted in a tertiary specialist hospital. An MTB case 88	  
series from the same hospital reported mortality in excess of 30% possibly reflecting 89	  
advanced stages of MTB disease. Bacillary burden might be higher in advanced cases of 90	  
MTB resulting in a high sensitivity of laboratory diagnosis. Patel et al noted lower Xpert 91	  
sensitivities in HIV negative patients with TBM (42%). In contrast our study included samples 92	  
from routine clinical practice, drawn from general and specialist hospitals across England. 93	  
Both prevalence of MTB and the bacillary burden of patients presenting with MTB are highly 94	  
context specific. Centrifugation and sample volumes might explain differences in sensitivity 95	  
of Xpert MTB/RIF in different settings:  Bahr et al describe a sensitivity of 72% when 96	  
comparing Xpert analysis of centrifuged CSF directly with Xpert on 2ml unprocessed CSF 97	  
(sensitivity 28%), and against microscopy and culture9. Median CSF samples in this 98	  
Ugandan study were large (6ml), whereas the NMRL is typically sent 0.5-1ml.  99	  
 100	  
Culture sensitivity is also a function of sample volume. To address the issue of false 101	  
negative cultures due to low CSF volumes this study took account of other culture results 102	  
within 7 days of the sample received for Xpert MTB/RIF testing. It is still possible that small 103	  
culture volumes and undisclosed TB treatment account for a proportion of Xpert MTB/RIF 104	  
‘false positive’ results. If samples were submitted with fuller clinical details, including HIV 105	  
status, imaging findings and cell counts we would have been able to employ a more robust 106	  
reference standard. 107	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A sensitivity of 55% compared to a suboptimal reference standard (culture) is unlikely 108	  
to impact heavily on clinical decision-making. At best a positive test result will confirm clinical 109	  
suspicion and enable a clinician to stop broad-spectrum antibiotics. In settings with a high 110	  
prevalence of rifampicin resistance, Xpert MTB/RIF results may confer some value regarding 111	  
rpoB mutations. Bahr et al (9) conclude a positive  culture or Xpert should be the laboratory 112	  
diagnostic standard and a negative Xpert MTB/RIF result should not outweigh a high level of 113	  
clinical suspicion10. . 114	  
 115	  
 116	  
 117	  
Table 1: Xpert MTB/RIF compared to culture for identification of Mycobacterium 118	  
tuberculosis complex 119	  
 Culture positive Culture negative Total 
Xpert MTB/RIF 
positive 
20 13* 33 
Xpert MTB/RIF 
negative 
17 690** 707 
Total 37 703 740 
  120	  
* Includes 5 instances where specimen was not culture positive but a contemporary CSF 121	  
specimen was culture positive  122	  
**Includes  3  instances where other contemporary CSF/CNS cultures were positive for M. 123	  
tuberculosis 124	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Table 2: Xpert MTB/RIF compared to culture, including contemporary  (within 7 days) 125	  
CSF samples for identification of Mycobacterium tuberculosis complex 126	  
 Culture positive Culture negative Total 
Xpert MTB/RIF 
positive 
25 3* 28 
Xpert MTB/RIF 
negative 
20 687 707 
Total 45 690 735 
 127	  
*5 Xpert MTB/RIF positive and MGIT culture negative results were excluded as request 128	  
forms stated the patients were on TB treatment 129	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